Opinion

Video

Current Landscape of Bispecific Therapies for RRMM

Key Takeaways

  • Bispecific therapies target both tumor antigens and T-cell receptors, enhancing immune responses against myeloma cells in RRMM.
  • Several bispecific antibodies are approved or in clinical trials, showing promise in overcoming resistance to conventional therapies.
SHOW MORE

Panelists discuss how bispecific T-cell–engaging therapies targeting BCMA, GPRC5D, and FcRH5 have emerged as novel immunotherapeutic approaches showing meaningful clinical activity for patients with heavily pretreated relapsed/refractory multiple

Video content above is prompted by the following

  • Provide a brief overview of the bispecific therapies currently available for the treatment of relapsed/refractory multiple myeloma (RRMM).
Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.